AE105

AE105 is a 9-mer peptide probe targeting the urokinase-type plasminogen activator receptor (uPAR) . AE105 binds tightly to the uPA-binding cavity of uPAR. AE105 can be used for the study of cancer[1].

254729-66-3

12352209

Transmembrane Glycoprotein

Immunology/Inflammation

Cancer

96.72

DMSO : 50 mg/mL (ultrasonic)

OC(C=C1)=CC=C1C[C@H](NC([C@@H](CCCNC(N)=N)NC([C@@H](CO)NC([C@@H](NC([C@@H](NC([C@@H](N)CC(O)=O)=O)CC2CCCCC2)=O)CC3=CC=CC=C3)=O)=O)=O)C(N[C@@H](CC(C)C)C(N[C@H](C(N[C@@H](CO)C(O)=O)=O)CC4=CNC5=CC=CC=C45)=O)=O

C60H83N13O15

1226.38

[1]Leth JM, et al. Targeted imaging of uPAR expression in vivo with cyclic AE105 variants. Sci Rep. 2023 Oct 11;13 (1) :17248.

Blue Ice

-80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)

http://file.medchemexpress.com/batch_PDF/HY-P11446/AE105-SDS-MedChemExpress.pdf

Peptides

No Development Reported